NCT06863493: An ongoing trial by SFA Therapeutics
This trial is ongoing. It must report results 1 year, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06863493 |
|---|---|
| Title | Study of the Safety and Effectiveness of Oral SFA-002 Compared to Oral Apremilast (Otezla) Tablets and Placebo in Mild to Severe Plaque Psoriasis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 1, 2025 |
| Completion date | June 1, 2026 |
| Required reporting date | June 1, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |